INMB
Price
$6.87
Change
-$1.15 (-14.34%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
159.46M
42 days until earnings call
NXTC
Price
$0.45
Change
-$0.05 (-10.00%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
12.66M
43 days until earnings call
Interact to see
Advertisement

INMB vs NXTC

Header iconINMB vs NXTC Comparison
Open Charts INMB vs NXTCBanner chart's image
INmune Bio
Price$6.87
Change-$1.15 (-14.34%)
Volume$26.68K
Capitalization159.46M
NextCure
Price$0.45
Change-$0.05 (-10.00%)
Volume$6.52K
Capitalization12.66M
INMB vs NXTC Comparison Chart in %
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. NXTC commentary
Jun 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and NXTC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2025
Stock price -- (INMB: $6.87 vs. NXTC: $0.45)
Brand notoriety: INMB and NXTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 477% vs. NXTC: 140%
Market capitalization -- INMB: $159.46M vs. NXTC: $12.66M
INMB [@Biotechnology] is valued at $159.46M. NXTC’s [@Biotechnology] market capitalization is $12.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $342.74B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, NXTC is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 4 TA indicator(s) are bullish while NXTC’s TA Score has 5 bullish TA indicator(s).

  • INMB’s TA Score: 4 bullish, 5 bearish.
  • NXTC’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NXTC is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а -12.82% price change this week, while NXTC (@Biotechnology) price change was -17.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.14%. For the same industry, the average monthly price growth was +8.92%, and the average quarterly price growth was +2.18%.

Reported Earning Dates

INMB is expected to report earnings on Jul 30, 2025.

NXTC is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($159M) has a higher market cap than NXTC($12.7M). INMB YTD gains are higher at: 47.109 vs. NXTC (-41.440). INMB has higher annual earnings (EBITDA): -41.52M vs. NXTC (-50.34M). NXTC has more cash in the bank: 55.9M vs. INMB (19.3M). INMB has less debt than NXTC: INMB (347K) vs NXTC (4.91M). INMB has higher revenues than NXTC: INMB (50K) vs NXTC (0).
INMBNXTCINMB / NXTC
Capitalization159M12.7M1,252%
EBITDA-41.52M-50.34M82%
Gain YTD47.109-41.440-114%
P/E RatioN/AN/A-
Revenue50K0-
Total Cash19.3M55.9M35%
Total Debt347K4.91M7%
FUNDAMENTALS RATINGS
INMB vs NXTC: Fundamental Ratings
INMB
NXTC
OUTLOOK RATING
1..100
94
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
4264
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (14) in the Biotechnology industry is significantly better than the same rating for INMB (92). This means that NXTC’s stock grew significantly faster than INMB’s over the last 12 months.

INMB's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as NXTC (100). This means that INMB’s stock grew similarly to NXTC’s over the last 12 months.

INMB's SMR Rating (99) in the Biotechnology industry is in the same range as NXTC (100). This means that INMB’s stock grew similarly to NXTC’s over the last 12 months.

INMB's Price Growth Rating (42) in the Biotechnology industry is in the same range as NXTC (64). This means that INMB’s stock grew similarly to NXTC’s over the last 12 months.

INMB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NXTC (100). This means that INMB’s stock grew similarly to NXTC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBNXTC
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CELH44.160.67
+1.54%
Celsius Holdings
TNL48.77-0.44
-0.89%
Travel + Leisure Co
DRUG27.69-0.55
-1.95%
Bright Minds Biosciences
NXGL2.50-0.07
-2.72%
NexGel
SNDX9.64-0.35
-3.50%
Syndax Pharmaceuticals

INMB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with ABCL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
-14.34%
ABCL - INMB
46%
Loosely correlated
-1.27%
BEAM - INMB
42%
Loosely correlated
+0.30%
CRSP - INMB
41%
Loosely correlated
+3.87%
PRME - INMB
41%
Loosely correlated
+7.67%
EYPT - INMB
40%
Loosely correlated
-1.01%
More

NXTC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NXTC has been loosely correlated with CYTK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NXTC jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NXTC
1D Price
Change %
NXTC100%
-10.08%
CYTK - NXTC
37%
Loosely correlated
-3.67%
ACET - NXTC
34%
Loosely correlated
-6.10%
ORMP - NXTC
33%
Poorly correlated
N/A
GOSS - NXTC
32%
Poorly correlated
-3.12%
SNPX - NXTC
28%
Poorly correlated
-8.20%
More